该基金股票持仓前十分别为：恒瑞医药、泽璟制药-U、百济神州-U、新诺威、人福医药、华东医药、 开立医疗、奕瑞科技、潮宏基、联影医疗。前十持仓占比合计72.80%。 来源：金融界 金融界2025年8月17日消息，中海医疗保健主题股票A(399011) 最新净值1.1610元，该基金近一周收益率 3.38%，近3个月收益率11.31%，今年来收益率14.50%。 中海医疗保健主题股票A基金成立于2012年3月7日，基金经理梁静静，截至2025年6月30日，中海医疗 保健主题股票A规模4.93亿元。 ...

Group 1 - The core viewpoint of the news is the performance and structure of the Zhonghai Healthcare Theme Stock A fund, which has seen a decline in recent trading days and has a significant portion of its holdings in specific pharmaceutical companies [1][2][3] Group 2 - As of June 19, Zhonghai Healthcare Theme Stock A has decreased by 1.28%, with a latest net value of 1.08 yuan, marking a cumulative decline of 8.09% over five consecutive trading days [1] - The fund was established in March 2012, with a total fund size of 519 million yuan and a cumulative return of 172.08% since inception [1] - The holder structure shows that as of the end of 2024, institutional investors hold 5.9 million shares (10.54% of total shares), while individual investors hold 49.8 million shares (89.46% of total shares) [1] - The current fund manager, Liang Jingjing, has a background in pharmaceutical chemistry and has held various research positions before becoming the fund manager [1] - As of March 31, 2025, the top ten holdings of the fund account for a total of 67.74%, with notable companies including Zai Lab (9.84%), BeiGene (8.53%), and WuXi AppTec (7.14%) [2]

Core Viewpoint - The article emphasizes that the current valuation of the China Medical Index (中证医疗) is at historically low levels, making it an opportune time for regular investment by ordinary investors [1]. Group 1: Market Analysis - The China Medical Index has experienced a significant adjustment period, with a peak in June 2015 and a low point at the end of 2018, followed by a recovery until the end of 2021, and has now been in a correction phase for approximately two years [5]. - The current adjustment has reached about 60% of its potential, indicating that the market may be nearing a bottom, although the duration of the adjustment is uncertain [5]. - A longer adjustment period is seen as beneficial for regular investors, as it allows for the accumulation of shares at lower prices, potentially leading to greater future gains [5]. Group 2: Investment Strategy - Ordinary investors are advised to focus on the Price-to-Book (PB) ratio for the China Medical Index, with a recommendation to start regular investments when the PB is below 20% [9]. - For more aggressive investors, a threshold of 25% to 30% is suggested for initiating investments [9]. - The article lists several actively managed medical-related funds that have been established for over six years and have a scale of over 500 million, highlighting their respective returns, with the top performer achieving a return of 178.62% since May 2017 [11]. Group 3: Fund Selection - The article provides a table of selected funds, showing their total returns and annualized returns over a period of approximately 6.2 years, with the best-performing fund yielding an annualized return of 18.00% [11]. - It emphasizes that despite current low valuations, all listed funds have positive long-term returns, suggesting that the issue lies more with the timing of investments rather than the funds themselves [12]. - The article advises investors to consider funds that have survived through market cycles and have demonstrated resilience [12].

Core Viewpoint - The China Ocean Medical Care Theme Stock A has experienced a decline of 0.85% on April 17, with a net value of 1.05 yuan, marking a cumulative drop of 1.95% over three consecutive trading days [1] Group 1: Fund Performance - The fund was established in March 2012 with a total size of 564 million yuan and has achieved a cumulative return of 165.78% since inception [1] - As of the end of 2024, the top ten holdings of the fund account for a total of 59.15% of the portfolio [2] Group 2: Holder Structure - As of the end of 2024, institutional investors hold 5.9 million shares, representing 10.54% of the total shares, while individual investors hold 49.8 million shares, accounting for 89.46% of the total [1] Group 3: Fund Management - The current fund manager, Ms. Liang Jingjing, has a master's degree in pharmaceutical chemistry from Peking University and has held various research positions in the pharmaceutical sector before becoming the fund manager [1]